Literature DB >> 16698410

Aminophylline in bradyasystolic cardiac arrest: a randomised placebo-controlled trial.

Riyad B Abu-Laban1, Caroline M McIntyre, James M Christenson, Catherina A van Beek, Grant D Innes, Robin K O'Brien, Karen P Wanger, R Douglas McKnight, Kenneth G Gin, Peter J Zed, Jeffrey Watts, Joe Puskaric, Iain A MacPhail, Ross G Berringer, Ruth A Milner.   

Abstract

BACKGROUND: Endogenous adenosine might cause or perpetuate bradyasystole. Our aim was to determine whether aminophylline, an adenosine antagonist, increases the rate of return of spontaneous circulation (ROSC) after out-of-hospital cardiac arrest.
METHODS: In a double-blind trial, we randomly assigned 971 patients older than 16 years with asystole or pulseless electrical activity at fewer than 60 beats per minute, and who were unresponsive to initial treatment with epinephrine and atropine, to receive intravenous aminophylline (250 mg, and an additional 250 mg if necessary) (n=486) or placebo (n=485). The patients were enrolled between January, 2001 and September, 2003, from 1886 people who had had cardiac arrests. Standard resuscitation measures were used for at least 10 mins after the study drug was administered. Analysis was by intention-to-treat. This trial is registered with the ClinicalTrials.gov registry with the number NCT00312273.
FINDINGS: Baseline characteristics and survival predictors were similar in both groups. The median time from the arrival of the advanced life-support paramedic team to study drug administration was 13 min. The proportion of patients who had an ROSC was 24.5% in the aminophylline group and 23.7% in the placebo group (difference 0.8%; 95% CI -4.6% to 6.2%; p=0.778). The proportion of patients with non-sinus tachyarrhythmias after study drug administration was 34.6% in the aminophylline group and 26.2% in the placebo group (p=0.004). Survival to hospital admission and survival to hospital discharge were not significantly different between the groups. A multivariate logistic regression analysis showed no evidence of a significant subgroup or interactive effect from aminophylline.
INTERPRETATION: Although aminophylline increases non-sinus tachyarrhythmias, we noted no evidence that it significantly increases the proportion of patients who achieve ROSC after bradyasystolic cardiac arrest.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698410     DOI: 10.1016/S0140-6736(06)68694-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

Review 1.  [The new 2005 resuscitation guidelines of the European Resuscitation Council: comments and supplements].

Authors:  V Wenzel; S Russo; H R Arntz; J Bahr; M A Baubin; B W Böttiger; B Dirks; V Dörges; C Eich; M Fischer; B Wolcke; S Schwab; W G Voelckel; H W Gervais
Journal:  Anaesthesist       Date:  2006-09       Impact factor: 1.041

2.  [Comments on the 2010 guidelines on cardiopulmonary resuscitation of the European Resuscitation Council].

Authors:  V Wenzel; S G Russo; H R Arntz; J Bahr; M A Baubin; B W Böttiger; B Dirks; U Kreimeier; M Fries; C Eich
Journal:  Anaesthesist       Date:  2010-12       Impact factor: 1.041

Review 3.  Aminophylline in bradyasystolic cardiac arrest.

Authors:  Elizabeth Hayward; Laurie Showler; Jasmeet Soar
Journal:  Emerg Med J       Date:  2007-08       Impact factor: 2.740

Review 4.  Recently published papers: dying Swans and other stories.

Authors:  Hannah Rose; Richard Venn
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

5.  Clinical trials in cardiac arrest and subarachnoid hemorrhage: lessons from the past and ideas for the future.

Authors:  Jennifer A Frontera
Journal:  Stroke Res Treat       Date:  2013-03-07

Review 6.  Aminophylline for bradyasystolic cardiac arrest in adults.

Authors:  Katrina F Hurley; Kirk Magee; Robert Green
Journal:  Cochrane Database Syst Rev       Date:  2015-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.